
Учебники / Revision Sinus Surgery Kountakis 2008
.pdf



|
|
318 |
|
Michael G. Stewart and Scott M. Rickert |
|
|
been removed and anatomy altered, but in fact the degree |
for “benchmarking” against known problems, but have |
|
|
|
of mucosal changes, and the response to medical treat- |
the disadvantage of being less sensitive to the effects of a |
|
|
|
ment, may be different in postsurgical sinuses. For exam- |
particular disease. For example, even the very successful |
|
|
|
ple, some degree of underlying mucosal thickening might |
treatment of specific problems like hearing loss or visual |
|
|
|
be expected and should perhaps be graded as “normal.” |
loss may result in only small changes on a global QOL |
|
|
|
In addition, the timing of outcome assessment is im- |
instrument. Disease-specific instruments are designed |
|
|
|
portant, and we should consider a different model in revi- |
with content that addresses the disease of interest, and are |
|
|
|
sion surgery – with respect to long-term outcome as well |
much more sensitive to changes in disease status; how- |
|
|
|
as “absolute” outcome. In many chronic diseases, the pa- |
ever, they have the disadvantage of not being comparable |
|
|
|
tient will never return to a normal state. In fact, gradual |
across disease states and therefore they can be difficult |
|
|
|
worsening in QOL might be expected. Therefore, suc- |
to interpret. In other words, what does an increase of 21 |
|
|
|
cessful treatment could limit the reduction in QOL (even |
points on scale X actually mean to a patient or interpret- |
|
|
|
though it still declines), or prolong the time before reach- |
ing physician? |
|
|
|
ing a certain level. For example, a patient with chronic |
■ In the assessment of symptoms or QOL, it is also im- |
|
|
|
renal failure may always require dialysis, but additional |
||
|
|
treatment could still improve QOL and be a desirable |
portant to keep in mind that patients without disease |
|
36 |
|
|||
|
adjunct. Similarly, in patients with polyposis or other |
will usually not score 0 (or 100) on scales. |
||
|
|
chronic mucosal diseases such as cystic fibrosis, need |
As an example, in one study of the Sino-Nasal Outcome |
|
|
|
|||
|
|
for revision surgery should not necessarily be counted as |
||
|
|
“failure,” and short-term improvements in health status |
Tool – 16 items, patients with rhinosinusitis scored an av- |
|
|
|
or QOL could be considered successful outcomes. On |
erage of 22.4 (on a scale of 0–48), and patients with ear |
|
|
|
the other hand, revision surgery can still result in disease |
disease scored a mean of 10.5. Other studies have shown |
|
|
|
resolution in many cases, so chronic status and eventual |
similar results. So, the baseline or “normal” score should |
|
|
|
failure is not necessarily the norm. |
be taken into account when reviewing results in any pop- |
|
|
|
■ Outcomes assessed in chronic rhinosinusitis can be |
ulation. |
|
|
|
■ The popularity and use of QOL tools has grown sig- |
||
|
|
divided into two general categories: subjective and |
||
|
|
objective. Both have been reported frequently in the |
nificantly, and in general the systematic assessment of |
|
|
|
literature, and clinicians typically use both types of |
QOL yields important information about what patients |
|
|
|
outcome in their everyday evaluations. |
are feeling, and the true effects of many treatments. |
|
|
|
|
|
■ Most QOL instruments are validated to measure QOL |
|
|
|
|
in populations, not individual patients. |
|
|
|
|
■ QOL instruments might not be the best tools for as- |
|
|
Subjective Outcomes |
|
|
|
|
|
sessment of outcome after changes in treatment – par- |
|
|
|
|
|
|
|
|
|
|
|
|
|
Symptoms are a key issue in rhinosinusitis, and are often |
ticularly in the very short term. |
|
|
|
the primary reason that patients seek initial medical at- |
However, the use of QOL instruments is often not fully |
|
|
|
tention and return for further treatment. In fact, at one |
||
|
|
time, an international task force on rhinosinusitis used the |
understood. For example, most QOL instruments are val- |
|
|
|
presence of symptoms as the definition of the disease [15]. |
idated to measure QOL in populations, not individual pa- |
|
|
|
This was problematic, however, because some patients |
tients. The statistical criteria for discrimination between |
|
|
|
with symptoms do not actually have rhinosinusitis. Sub- |
individual patients are more stringent. In addition, many |
|
|
|
sequent publications have moved away from the concept |
instruments are designed to measure QOL averaged over |
|
|
|
of symptoms as definitional, but nevertheless symptoms |
a recent period of time, not day-to-day changes. For ex- |
|
|
|
are a key component of the disease and a major driver |
ample, items on the SF-36 global instrument ask about |
|
|
|
of patient’s behavior. There is currently no standardized, |
the previous 4 weeks, and items on the Chronic Sinusitis |
|
|
|
validated tool to measure symptom burden in rhinosi- |
Survey ask about the previous 8 weeks. Therefore, QOL |
|
|
|
nusitis, although some tools have been reported [4]. |
instruments might not be the best tools for assessment of |
|
|
|
An additional assessment of subjective outcome is |
outcome after changes in treatment – particularly in the |
|
|
|
QOL, which is measured using validated instruments. |
very short term. In such cases, the presence and severity |
|
|
|
QOL instruments are generally divided into two types – |
of symptoms might be more useful. However, there needs |
|
|
|
global (or “generic”), and disease-specific. Both global |
to be some agreement on exactly which symptoms are |
|
|
|
and disease-specific instruments have advantages and |
important to measure. A simple listing of potential symp- |
|
|
|
disadvantages. Global instruments have the advantage |
toms will not suffice, because it will give equal “weight” |
|
|
|
of being comparable between diseases and can be used |
to each symptom. For example, if there are ten possible |




